Islamabad, Aug 3, 2025: In a remarkable milestone, Pakistani pharmaceutical exports soared to an all-time high of $457 million in FY25, marking a robust 34% year-on-year growth. This exceptional performance underscores the growing strength and global competitiveness of Pakistan’s pharmaceutical industry.
The sector’s steady upward trend is evident when compared to previous years — $341 million in FY24, $328 million in FY23, and $269 million in FY22. Experts attribute this consistent growth to favorable policy changes, particularly the deregulation of non-essential drug pricing. This move allowed pharmaceutical manufacturers greater flexibility to invest in product innovation and international expansion.
Market analysts anticipate even greater export potential in the ongoing fiscal year, supported by improved compliance with international quality standards, rising demand for affordable generic drugs, and Pakistan’s expanding footprint in emerging markets across Africa, Central Asia, and the Middle East.
The pharmaceutical sector, once a modest contributor to national exports, is now gaining recognition as a strategic export industry. Local manufacturers are not only enhancing their production capabilities but also forming global partnerships, leading to increased registration of Pakistani medicines in foreign markets.
Read More: Top 10 Pharmaceutical Companies in Pakistan: Industry Leaders, Products & Market Share
Industry experts believe if this momentum continues, Pakistani pharmaceutical exports could soon cross the half-billion-dollar mark, strengthening the country’s position as a competitive player in global healthcare supply chains.
